Organon (OGN) Common Equity (2020 - 2026)

Organon's Common Equity history runs 7 years deep, the most recent figure standing at $903.0 million for Q1 2026.

• In Q1 2026, Common Equity rose 66.61% year-over-year to $903.0 million; the TTM figure through Mar 2026 stood at $903.0 million (up 66.61% YoY), while the FY2025 annual figure was $752.0 million, up 59.32% from the prior year.
• Common Equity was $903.0 million for Q1 2026 at Organon, up from $752.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $906.0 million in Q3 2025 to a low of -$1.2 billion in Q1 2022.
• Historically, Common Equity has averaged -$76.6 million across 5 years, with a median of $48.0 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Common Equity slumped 126.47% in 2022, then soared 1029.17% in 2025.
• A 5-year view of Common Equity shows it stood at -$892.0 million in 2022, then soared by 92.15% to -$70.0 million in 2023, then soared by 774.29% to $472.0 million in 2024, then jumped by 59.32% to $752.0 million in 2025, then rose by 20.08% to $903.0 million in 2026.
• The last three Common Equity figures came in at $903.0 million (Q1 2026), $752.0 million (Q4 2025), and $906.0 million (Q3 2025), per Business Quant data.